Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Trial Profile

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Interferon beta-1b (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 29 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 03 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Aug 2017 Planned End Date changed from 30 Jul 2017 to 8 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top